Despite advances in early detection and targeted therapies, the prognosis for patients with metastatic breast cancer, particularly those with triple-negative breast cancer (TNBC) and HER2-positive breast cancer, remains poor. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.